TransMedics Group, Inc. Stock News

TransMedics' Q1 results showcased explosive 48% revenue growth and margin recovery, reaffirming my bullish thesis on its OCS technology and logistics moat. Despite new risks like competition and logistics costs, TMDX's execution, clinical edge, and management's ambitious growth targets support long-term market dominance. Valuation remains compelling: strong EPS growth and frequent estimate beat...

With the way negative stock market sentiment  has piled up recently, short squeezes have generated some massive returns.

In May, three stocks that released earnings stood out due to their massive sales beats. These names are mid-cap companies with market capitalizations between $2 billion and $10 billion.

NEW YORK, June 10, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of TransMedics Group, Inc. (NASDAQ: TMDX) breached their fiduciary duties to shareholders.

As the broader market stages a sharp rebound from its April lows, several sectors, industries, and stocks have quietly emerged as leaders. Among them, the medical technology industry, known for its innovation and growth potential, has stood out.

NEW YORK , May 27, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of TransMedics Group, Inc. (NASDAQ: TMDX)  breached their fiduciary duties to shareholders.  According to a federal securities lawsuit, Insiders at TransMedics caused the company to misrepresent or fail to disclose (1) TransMedics used kickbacks, fr...

ANDOVER, Mass. , May 27, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on May 21, 2025, TransMedics granted non-qualified stock options to purchase an aggregate of 9,940 shares of its common stock and an aggreg...

TransMedics delivered a stellar Q1, beating revenue and EPS estimates, and raised FY25 guidance, showcasing robust growth and execution. I see significant upside from expanding organ utilization, especially with the upcoming kidney market and international opportunities, which meaningfully increase TAM. Despite risks like share dilution, logistics complexity, and regulatory hurdles, TMDX's moat...